Fig. 1. Shh expression and signaling are significantly upregulated in CML-variants and non-compliant patients.

A Graph representing fold change in Shh and Gli1-mRNA (in log2 scale) from chronic phase CML (CML-CP) patients (n = 3; blue data points); chronic phase CML with variant chromosomal translocation (n = 5; orange) and non-compliant patients (n = 1; red) using RT-PCR. Reference line (black dotted line) represents the expression in normalizing control (K562 cells). P values, *<0.05. Statistical analysis done using t-test. B Immunohistochemistry for Shh and Patched1 using bone biopsy samples of CML patients in CML-CP (9:22; CML-3&8) and chronic phase CML with variant chromosomal translocation (CML-7, CML12). Blue, hematoxylin. Scale bar 20 μm. C Heatmap showing expression of Shh signaling pathway genes (as per KEGG pathway) using RNA-seq data from high-risk CML patients¹. Patients were in Chronic Phase at diagnosis (CP Dx.) with progression to lymphoid blast crisis (LBC) or myeloid blast crisis (MBC). Three patients were in MBC at diagnosis (MBC Dx.). Two patients were in accelerated phase at diagnosis (AP Dx.) and progressed to MBC. The gene expression profiles depict the clear distinction between CML-CP from other stages.